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INTRODUCTION 
 
Clearance concepts were introduced into the 
pharmacokinetics discipline in the 1970s by Gillette 
(1), Rowland et al. (2), and Wilkinson and Shand (3). 
As elegantly described by Benet (4) in a tribute to Dr. 
Rowland for his contributions in this area, many 
experimental observations could not be explained by 
the prevalent pharmacokinetic theories in the late 
1960s and early 1970s before the introduction of 
clearance concepts. In contrast to the heavy reliance 
on mathematical relationships for description of the 
pharmacokinetic behavior of drugs in pre-clearance 
era, the clearance concepts were based on the 
relationship between organ clearance and 
physiologic parameters, such as drug free (unbound) 
fraction in blood (fub), intrinsic capability of the 
eliminating organ to remove the free drug from the 
body (Cl’int), and the organ blood flow (Q). Since the 
1970s, the clearance concepts have been widely used 
in the literature to explain the pharmacokinetic 
behavior of many drugs and the effects of changes in 
the physiological parameters, as a result of disease 
states, drug-drug interactions, or age, on the blood 
concentration-time courses of drugs after different 
routes of administration. The purpose of this 
communication is to 1) briefly review the 
fundamental principles of clearance concepts and 2) 
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ABSTRACT: Clearance concepts were introduced into the pharmacokinetics discipline in the 1970s and since 
then have played a major role in characterization of the pharmacokinetic behavior of drugs. These concepts are 
based on the relationship between organ extraction ratio or clearance and physiologic parameters such as the organ 
blood flow and the intrinsic capability of the eliminating organ to remove the free (unbound) drug from the body. 
Several theoretical models have been developed, which define these relationships and may be used to predict the 
effects of changes in the physiological parameters on various pharmacokinetic parameters of drugs, such as drug 
clearance. In this communication, the fundamentals of the two most widely used models of hepatic metabolism, 
namely the well-stirred (venous equilibrium) and parallel-tube (sinusoidal perfusion) models, are reviewed. 
Additionally, the assumptions inherent to these models and the differences between them in terms of their 
predictive behavior are discussed. The effects of changes in the physiologic determinants of clearance on the blood 
concentration-time profiles of drugs with low and high extraction ratio are also presented using numerical 
examples. Lastly, interesting and unusual examples from the literature are provided where these concepts have 
been applied beyond their widely known applications. These examples include estimation of the oral 
bioavailability of drugs in the absence of otherwise needed intravenous data, differentiation between the role of 
liver and gut in the first-pass loss of drugs, and distinction between the incomplete absorption and first-pass 
metabolism in the gastrointestinal tract after the oral administration of drugs. It is concluded that the clearance 
concepts are a powerful tool in explaining the pharmacokinetics of drugs and predicting the changes in their blood 
concentration-time courses when the underlying physiologic parameters are altered due to age, disease states, or 
drug interactions.    
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89 
to present examples of the application of clearance 
concepts in interpretation of pharmacokinetic 
behavior of drugs. 
 
FUNDAMENTAL CONCEPTS 
 
Organ Clearance 
The concept of organ clearance and loss of drugs 
across an organ of elimination have been described 
in detail previously (5-7). Briefly, the clearance of an 
eliminating organ (Cli) is the volume of blood 
cleared of drug by that organ per unit of time, which 
is defined by the following equation: 
 
𝐶𝑙௜ = 𝑄௜ ∙ 𝐸௜       (1) 
 
where Ei is the organ extraction ratio or the fraction 
of the drug, which is eliminated by the organ during 
one passage, and Qi represents the blood flow to the 
organ. The 𝐸௜  value may be estimated from the 
steady state concentration of drug entering (Cin) and 
exiting (Cout) the eliminating organ, as shown in 
Equation 2: 
 
𝐸௜ =
஼೔೙ି஼೚ೠ೟
஼೔೙
       (2) 
 
For hepatic clearance (Clh), Equation 1 may be 
rewritten in terms of hepatic extraction ratio (Eh) and 
blood flow (Qh): 
 
𝐶𝑙௛ = 𝑄௛ ∙ 𝐸௛       (3) 
 
Because the lower and upper limits of Eh are zero and 
1, the Clh of drugs could potentially range from zero 
to Qh.  
 
Physiologic Determinants of Eh and Clh 
In the liver, drugs travel through the sinusoids and 
come in contact with the hepatocytes, which contain 
enzymes for drug metabolism. The drug in the 
sinusoids may be in two forms of protein bound and 
free. The extent of extraction (and clearance) of 
drugs depends on at least 3 factors described below. 
1. Free fraction of the drug in blood (fub): It is 
generally assumed that only the free drug may enter 
the hepatocytes, where it is subject to metabolism or 
biliary excretion. As a general rule, the higher fub, the 
larger are Eh and Clh.  
2. Intrinsic clearance of the free drug (Cl’int): 
This parameter is the intrinsic capability of the liver 
to remove the drug from the blood in the absence of 
any flow limitations. In other words, this is the 
hypothetical volume of blood the liver could clear 
per unit of time if Qh were unlimited. As a general 
rule, when Cl’int increases, both Eh and Clh will 
increase. 
3. The blood flow (Qh): Qh affects Eh and Clh 
differently. As the flow increases, the extraction of 
the drug into the hepatocytes decreases (less time for 
extraction). However, because Clh is a function of 
both Eh and Qh (Equation 3), overall, an increase in 
Qh results in an increase (less than proportional) in 
Clh. 
 
Effects of Physiologic Determinants of Eh and Clh 
for High and Low Eh Drugs 
The statements above are generally true for any drug 
with any Eh . However, the extent by which each of 
these three parameters (fub, Qh, and Cl’int) affects Eh 
and Clh is dependent on the initial Eh of the drug. For 
drugs with high metabolic capacity (such as 
propranolol), Cl’int may potentially be several-fold 
higher than the liver blood flow. Therefore, for these 
drugs, Clh is limited by perfusion (Qh). Because of 
high intrinsic metabolic capacity, these drugs have 
high (close to 1) extraction ratios. At the other 
extreme, there are drugs for which Cl’int is much less 
than Qh. Therefore, Clh of these drugs is limited by 
their Cl’int. These drugs have low Eh (close to zero).  
 
Models of Hepatic Clearance 
There are different models that may be used to define 
the relationship among physiologic parameters and 
hepatic extraction ratio or clearance (8-15). Two of 
the major models introduced in the 1970s, which are 
still widely used, are the well-stirred (or venous 
equilibrium) and parallel tube (or sinusoidal 
perfusion) models (8-10). These two models are 
graphically shown in Fig. 1. As shown in the figure, 
the well-stirred model assumes that the eliminating 
organ (liver) is a single well-stirred compartment, 
with the free concentration of the drug in the blood 
leaving the liver being in equilibrium with and equal 
to the free drug concentration in the liver water. The 
parallel-tube model assumes that the liver is 
composed of identical parallel tubes with even 
distribution of the enzymes along the length of the 
tube, and that the blood concentration of free drug 
decreases exponentially along the length of the tube 
(Fig. 1). For the parallel-tube model, the average 
concentration of the drug in the liver is estimated as 
the logarithmic averages of the inlet (Cin) and outlet 
(Cout) concentrations.  
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 In both models, the hepatic clearance (Clh) is 
related to the hepatic blood flow (Qh) and the 
extraction ratio (Eh) by Equation 3. Additionally, in 
both models, hepatic availability (Fh), which is 
defined by the ஼೚ೠ೟
஼೔೙
 ratio, is related to Eh using the 
following equation: 
 
Fh = 1– Eh       (4) 
 
As demonstrated in Equation 4, Fh is the fraction of 
the drug escaping extraction by the liver. In other 
words, it is the fraction of the concentration entering 
the liver, which exits the liver intact. 
 
Well-Stirred Model 
For the well-stirred model, the relationships between 
Eh or Fh and fub, Cl’int, and Qh are defined by the 
following equations: 
 
𝐸௛ =
௙ೠ್∙஼௟೔೙೟
ᇲ
ொ೓ା௙ೠ್∙஼௟೔೙೟
ᇲ        (5) 
 
𝐹௛ = 1 − 𝐸௛ = 1 −
௙ೠ್∙஼௟೔೙೟
ᇲ
ொ೓ା௙ೠ್∙஼௟೔೙೟
ᇲ =
ொ೓
ொ೓ା௙ೠ್∙஼௟೔೙೟
ᇲ     (6) 
 
 
Therefore, based on the well-stirred model, Clh may 
be defined in terms of its individual components 
using the following equation:  
 
𝐶𝑙௛ = 𝑄௛ ×
௙ೠ್∙஼௟೔೙೟
ᇲ
ொ೓ା௙ೠ್∙஼௟೔೙೟
ᇲ        (7) 
 
The 𝐶𝑙௜௡௧ᇱ  parameter, which is an indication of the 
intrinsic capability of the liver to remove the drug 
from the body in the absence of any flow limitation, 
is related to the sum of activities of the enzymes that 
metabolize the drug: 
 
𝐶𝑙௜௡௧ᇱ = ∑
௏೘ೌೣ,೔
௄೘,೔ା஼ಽ,ೠ
௡
௜ୀଵ        (8) 
 
 
 
 
Figure 1. Graphical representations of the well-stirred (top) and parallel-tube (bottom) models of organ clearance. Cin and 
Cout represent concentration of the drug entering and leaving the liver, respectively, and the dashed lines indicate the unbound 
concentration of the drug in the liver along the direction of flow. Adapted from reference (8).  
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 In the above equation, Vmax,i, Km,i, and CL,u refer to the 
maximum velocity and Michaelis-Menten constant 
of the individual enzymes involved in the 
metabolism of the drug and the unbound 
concentration of the drug in the liver, respectively. If 
the drug is also subject to biliary excretion, Cl’int is 
the summation of both metabolic and excretory 
intrinsic clearances. 
For simplicity, some investigators use Clint, 
instead of the term 𝑓௨௕ ∙ 𝐶𝑙௜௡௧ᇱ , in Equations 5, 6 and 
7: 
𝐸௛ =
஼௟೔೙೟
ொ೓ା஼௟೔೙೟
       (9) 
 
𝐹௛ =
ொ೓
ொ೓ା஼௟೔೙೟
       (10) 
 
𝐶𝑙௛ = 𝑄௛ ×
஼௟೔೙೟
ொ೓ା஼௟೔೙೟
       (11) 
 
The term Clint is defined as the intrinsic clearance of 
the total (free plus unbound) drug. Equation 9 may 
be rearranged to estimate Clint when the Eh and Qh 
values are known: 
 
𝐶𝑙௜௡௧ =
ா೓×ொ೓
ଵିா೓
= ா೓×ொ೓
ி೓
       (12) 
 
For drugs with high Eh (i.e., high values of Clint 
relative to Qh), Equations 9, 10, and 11 would 
simplify to the following equations: 
 
𝐸௛ =
஼௟೔೙೟
ொ೓(≪஼௟೔೙೟)ା஼௟೔೙೟
≈ ஼௟೔೙೟
஼௟೔೙೟
≈ 1       (13) 
 
𝐹௛ =
ொ೓
ொ೓ (≪஼௟೔೙೟)ା஼௟೔೙೟
≈ ொ೓
஼௟೔೙೟
       (14) 
 
𝐶𝑙௛ = 𝑄௛ ×
஼௟೔೙೟
ொ೓ (≪஼௟೔೙೟)ା஼௟೔೙೟
≈ 𝑄௛ ×
஼௟೔೙೟
஼௟೔೙೟
≈ 𝑄௛       
(15) 
 
These approximate equations indicate that for drugs 
with very high Eh (close to 1), Fh is proportionally 
related to Qh and inversely related to 𝐶𝑙௜௡௧. 
Additionally, the Clh of these drugs is perfusion-
limited. Examples of drugs with high Eh include 
propranolol, verapamil, morphine, meperidine, 
nitroglycerine, and lidocaine. 
On the other hand, for drugs with low Eh (i.e., 
low values of Clint relative to Qh), Eh is directly 
related to Clint and inversely related Qh, Fh is almost 
close to 1, and Clh of the drug becomes almost equal 
to Clint or 𝑓௨௕ ∙ 𝐶𝑙௜௡௧ᇱ : 
 
𝐸௛ =
஼௟೔೙೟
ொ೓ା஼௟೔೙೟ (≪ொ೓)
≈ ஼௟೔೙೟
ொ೓
       (16) 
𝐹௛ =
ொ೓
ொ೓ା஼௟೔೙೟ (≪ொ೓)
≈ ொ೓
ொ೓
≈ 1       (17) 
 
𝐶𝑙௛ = 𝑄௛ ×
஼௟೔೙೟
ொ೓ା஼ ೔೙೟ (≪ொ೓)
≈ 𝑄௛ ×
஼௟೔೙೟
ொ೓
≈ 𝐶𝑙௜௡௧ ≈
𝑓௨௕ ∙ 𝐶𝑙௜௡௧ᇱ        (18) 
 
Examples of drugs with low Eh include warfarin, 
tolbutamide, diazepam, erythromycin, and 
theophylline. 
 
Parallel-Tube Model 
For the parallel-tube model, the relationships 
between Eh, Fh, or Clh and fub, Cl’int, and Qh are given 
below: 
𝐸௛ = 1 − 𝑒
ష೑ೠ್∙಴೗೔೙೟
ᇲ
ೂ೓ = 1 − 𝑒
ష಴೗೔೙೟
ೂ೓        (19) 
 
𝐹௛ = 1 − 𝐸௛ = 𝑒
ష೑ೠ್∙಴೗೔೙೟
ᇲ
ೂ೓ = 𝑒
ష಴೗೔೙೟
ೂ೓        (20) 
 
𝐶𝑙௛ = 𝑄௛ ∙ 𝐸௛ = 𝑄௛ ൭1 − 𝑒
ష೑ೠ್∙಴೗೔೙೟
ᇲ
ೂ೓ ൱ = 𝑄௛ ቆ1 −
𝑒
ష಴೗೔೙೟
ೂ೓ ቇ       (21) 
 
If Equation 19 or Equation 20 for the parallel tube 
model is to be used for the estimation of Clint when 
Eh and Qh are known, this may be done by taking the 
natural logarithm of the exponential term: 
 
ln(1 − 𝐸௛) =
ି஼௟೔೙೟
ொ೓
       (22) 
 
𝐶𝑙௜௡௧ = −𝑄௛ × ln(1 − 𝐸௛) = −𝑄௛ × ln𝐹௛       (23) 
 
Similar to the well-stirred model, for drugs with 
the very high or very low Eh, Equation 21 predicts 
that the Clh is limited by Qh or Clint (𝑓௨௕ ∙ 𝐶𝑙௜௡௧ᇱ ), 
respectively.  
 
For both models, the above equations assume 
that the permeability of the drug across the interstitial 
space and hepatocyte membranes is much higher 
than the Cl’int of the drug. Therefore, permeability is 
not the rate-limiting step in the elimination of the 
drug. However, if permeability becomes an issue, 
these equations need to be modified to account for 
the permeability parameters. Pravastatin is an 
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 example of drugs with uptake permeability-limited 
elimination (16).  
 
Differences between the Models in Predictions of 
Pharmacokinetics of Drugs 
Simulations have shown (8) that the two models 
behave relatively close to each other with regard to 
the effects of changes in fub and/or Cl’int (i.e., Clint). 
However, the major difference between the two 
models is with regard to their prediction of hepatic 
availability (Fh) based on changes in Qh for the high 
Eh dugs. Although the differences between the two 
models for the prediction of Eh even at high Eh is 
relatively small (30%), this translates to very large 
differences between the two models in prediction of 
Fh and oral AUC of drugs with high hepatic Eh (8). 
This is because at high Eh, Fh changes linearly 
relative to Qh for the well-stirred model as 
demonstrated in Equation 14 ( 𝐹௛ ≈ 𝑄௛ 𝐶𝑙௜௡௧⁄ ). 
However, for the parallel-tube model, Fh changes 
exponentially relative to Qh, as demonstrated in 
Equation 20 ( 𝐹௛ = 𝑒ି஼௟೔೙೟ ொ೓⁄ ). Therefore, at the 
extreme Eh value of 0.99, the difference in prediction 
of Fh for the two models may be over a thousand-fold 
(8). Further experimental studies (9, 10) have 
suggested that for most drugs, such as lidocaine, the 
well-stirred model predicts the clearance of the drug 
better. Therefore, most investigators use the well-
stirred model in their analysis of hepatic clearance of 
drugs, unless it is proven to be not applicable. 
However, it has recently been argued that the studies 
designed to distinguish between the two models are 
inherently biased towards the well-stirred model (17), 
a notion that is subject to debate (18) and outside the 
scope of this review. Because of the prevalence of 
the use of the well-stirred model in the literature, we 
will use this model for the remainder of our 
discussion and case studies presented here. 
 
The Relationship between Hepatic Availability 
(Fh) and Oral Bioavailability (F) 
Figure 2 depicts the potential barriers for an oral dose 
to reach systemic circulation, which may result in the 
loss of drugs after their oral administration (19). 
After the intravenous dosing, however, the drug is 
introduced directly into the systemic circulation. 
Therefore, the oral bioavailability of drugs (F), or the 
extent by which an oral dose enters the systemic 
circulation, is defined by the ratio of the blood AUCs 
after the oral and intravenous administration. As 
𝐹 = 𝐹௔௕ × 𝐹௚ × 𝐹௛      (24) 
𝐹 = 0.4 × 0.5 × 0.3 = 0.06 
 
It should be noted that if the absorption of the 
drug is complete and there is no gastrointestinal 
metabolism (i.e., 𝐹௔௕ × 𝐹௚ = 1 ), the hepatic 
availability and oral bioavailability would be the 
same. In other words, the oral bioavailability of 
drugs cannot be more than their hepatic availability. 
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demonstrated in Fig. 2, after oral administration, the 
drug is absorbed from the gastrointestinal tract and 
passes through the liver before reaching the systemic 
circulation. This means the orally-administered drug 
entering the systemic circulation has to pass through 
the liver first (“first-pass effect”). This is different 
from the intravenous administration, where the drug 
is directly introduced into the systemic circulation 
without passing through the liver first (Fig. 2). 
Obviously, in both cases (intravenous and oral), after 
reaching the systemic circulation, a fraction of the 
drug will be passing through different organs, 
including the liver, with each circulation. However, 
the oral drug has one extra “pass” through the liver 
during the absorption process. Therefore, the oral 
bioavailability of drugs (F) is influenced by their 
hepatic availability (Fh). In addition to Fh, F is also 
affected by the loss of drug during the absorption 
process such as incomplete absorption and/or 
metabolism/degradation in the gastrointestinal tract 
(Fig. 2). To clarify this, consider an example where 
200 mg of a drug is administered orally to a patient. 
Assume only 40% of the dose is absorbed orally 
(fraction of the dose absorbed or Fab of 0.4), which 
means only 80 mg reaches the enterocytes. If the 
drug is subject to metabolism in the gut, resulting in 
50% of the drug escaping metabolism in the 
enterocytes (Fg of 0.5), only 40 mg of the drug 
reaches the liver. Assuming a hepatic Eh of 0.7 (Fh or 
hepatic availability of 0.3), 30% of the drug reaching 
the liver will pass intact into the systemic circulation 
(0.3 x 40 mg or 12 mg). This means that out of the 
200-mg oral dose, only 12 mg reaches the systemic 
circulation. Therefore, the oral bioavailability of this 
drug (relative to intravenous administration), which 
may be estimated experimentally by the oral AUC: 
intravenous AUC ratio, is only 0.06 or 6% (12/200). 
The following equation describes the relationship 
among F, Fab, Fg, and Fh: 
 
  
 
Figure 2. Barriers to drug entry into the systemic circulation after oral administration of drugs. For comparison, direct 
introduction of the drug into the systemic circulation after intravenous administration is also shown. Abbreviations: Fab, 
fraction of the dose absorbed; Fg, fraction of the dose escaping gut metabolism; Fh, fraction of the dose escaping liver 
metabolism; Eg, gut extraction ratio; Eh, liver extraction ratio. Adapted from reference (19). 
 
 
Effects of Qh, fub, and Cl’int on the Blood 
Concentration-Time Courses of Low and High Eh 
Drugs 
After intravenous dosing, the only pharmacokinetic 
parameter that affects the AUC of a drug is its 
systemic Cl. However, after oral dosing, the AUC is 
dependent on both the systemic Cl and oral 
availability (F), both of which are subject to change 
if fub, Cl’int, and/or Qh is changed. Here, we examine 
the effects of a change in the determinants of Clh of 
drugs on their blood concentration-time profiles for 
the low and high Eh drugs. For simplicity, we assume 
that the drug is eliminated by hepatic metabolism 
only, which means the systemic Cl is equal to Clh. 
Additionally, we assume that the oral absorption of 
the drug is complete with no metabolism in the gut, 
which means the oral availability of the drug (F) is 
equal to its hepatic availability (Fh).  
 
Low Extraction Ratio Drugs 
The characteristics of a hypothetical drug with a very 
low Eh value of 0.0011 under normal conditions and 
when the Clint (Cl’int or fub) or Qh values are 
increased by a factor of 2 are listed in Table 1. 
Additionally, the corresponding blood 
concentration-time courses of the drug are presented 
in Fig. 3. After selection of Cl’int and fub values for 
this drug to generate a low Clint value (0.1 L/h) 
relative to the hepatic blood flow (90 L/h), the Eh, Fh, 
and Clh are calculated using Equations 9, 4, and 3, 
respectively. As stated above, for a low Eh drug, Clh 
is expected to be close to Clint or 𝑓௨௕ ∙ 𝐶𝑙௜௡௧ᇱ . This is 
also shown in Table 1 for Control subjects, where the 
Clint and Clh values are almost identical for this 
hypothetical drug. Additionally, Fh for this drug is 
very high (almost 1) (Table 1). Assuming a volume 
of distribution of 5 L, the half-life of the drug is 35 h 
in Control subjects (Table 1). As demonstrated in 
Table 1, the changes in either Cl’int or fub would 
produce the same net effect on the other kinetic 
parameters of the drug because they are both 
reflected in the Clint value. A two-fold increase in 
Cl’int or fub results in a two-fold increase in Clint, Eh, 
and Clh for this low Eh drug (Table 1). Additionally, 
a two-fold increase in Clh also results in a two-fold 
decrease in the half-life of the drug (Table 1). 
However, the Fh value of the drug remains close to 1, 
regardless of the changes in fub or Cl’int (Table 1). As 
demonstrated in Figs. 3A and 3B, a two-fold increase 
in Clint for a low Eh drug results in an almost two-fold 
increase in its Cl, which is demonstrated by a 
corresponding two-fold decrease in the AUC and 
half-life after both intravenous and oral dosing. An 
example of such change is the effects of co-
administration of warfarin, a low Eh drug, with 
rifampin, which induces the metabolism of warfarin 
(higher Cl’int), resulting in a higher clearance, lower 
AUC, and a shorter half-life (20). 
As for Qh, neither intravenous nor oral profile of 
a low Eh drug is affected by a change in Qh (Figs. 3C 
and 3D). Although a two-fold increase in Qh results 
in a two-fold decrease in Eh, the Clh value remains 
unchanged because the decrease in Eh is 
compensated by a corresponding increase in Qh 
(Table 1). This is consistent with the notion that the 
Cl of a low Eh drugs is mostly dependent on fub and 
Cl’int (Equation 18). Additionally, Fh of the drug is 
very high regardless of the change in Qh (Table 1).  
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 Figure 3. Effects of a two-fold increase in Clint (fub or Cl’int) (top panels) or Qh (bottom panels) on the blood concentration-
time courses of a hypothetical low Eh drug after intravenous (left) or oral (right) administration of a 50-mg dose of the drug. 
The kinetic parameters are listed in Table 1. 
 
Table 1. The pharmacokinetic parameters of a hypothetical drug a with low hepatic extraction ratio (Eh) in the absence 
(Control) and presence of changes in the intrinsic capability of the liver to remove the free drug (Cl’int), free drug fraction 
in blood (fub), or hepatic blood flow (Qh). 
Condition Cl’int 
(L/h) 
fub Clint 
(L/h) 
Qh 
(L/h) 
Ehb   Fhb   Clhb  
(L/h) 
V 
(L) 
t1/2c 
(h) 
Control  10 0.01 0.10 90 0.00111 0.999 0.0999 5 34.7 
 Cl’int x 2 20 0.01 0.20 90 0.00222 0.998 0.200 5 17.4 
 fub x 2 10 0.02 0.20 90 0.00222 0.998 0.200 5 17.4 
 Qh x 2 10 0.01 0.10 180 0.000555 0.999 0.0999 5 34.7 
a The hypothetical drug has a Cl’int of 10 L/h, a fub of 0.01, and a volume of distribution (V) of 5 L under baseline 
conditions, with elimination through the liver only. 
b Eh, Fh, and Clh were estimated from the values of Cl’int, fub, and Qh using Equations 9, 4, and 3, respectively. 
c Half-life (t1/2) is estimated from 𝑡ଵ/ଶ =
଴.଺ଽଷ×௏
஼௟
, where Cl is assumed to be equal to Clh. 
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 High Extraction Ratio Drugs 
The pharmacokinetic characteristics of a high Eh 
drug in the absence (Control) or presence of changes 
in Cl’int, fub, or Qh are listed in Table 2. Additionally, 
the corresponding blood concentration-time courses 
are shown in Fig. 4. The Clint of the drug in Control 
subjects (1500 L/h) is much more than the Qh of 90 
L/h, hence a high Eh of 0.943 (Table 2). As expected, 
the drug has a very low Fh value of 0.0566. 
Additionally, assuming a V of 400 L, the drug has a 
half-life of 3.26 h (Table 2). In contrast to the low Eh 
drug (Table 1), doubling the Clint by doubling either 
fub or Cl’int does not substantially affect the Eh, Clh, 
or half-life of this high Eh drug (Table 2). The lack 
of changes in the Clh of this high Eh drug after 
doubling Clint is predictable because the Clh of these 
drugs are mostly perfusion limited. However, the 
hepatic availability (and oral bioavailability) of the 
drug is reduced by almost 50% when Clint is 
increased by a factor of 2 (Table 2). This is because 
after oral dosing, the Fh of the high Eh drugs is almost 
linearly (inversely) related to their Clint (Equation 14). 
Consequently, whereas the blood concentration-time 
courses of the high Eh drug after the intravenous 
administration are insensitive to changes in Clint (no 
change in Cl) (Fig. 4A), the Fh, blood concentrations, 
and AUC of the drug after the oral administration are 
reduced by an almost 50% in the presence of a two-
fold increase in Clint (Fig. 4B). 
The above discussion clearly shows that the 
disease states and/or drug interactions that affect 
Cl’int and/or fub would be reflected in the blood 
concentration-time courses of high Eh drugs only 
after the oral dosing, but not after the intravenous 
administration (Figs. 4A and 4B).  
An example of such effect is the interaction 
between the enzyme inducer pentobarbital and the 
high Eh drug alprenolol reported by Alvan et al. (21). 
In that study, a single dose of alprenolol was 
administered intravenously or orally before and after 
10-14 daily doses of pentobarbital. Whereas 
pentobarbital reduced the AUC of the orally-
administered alprenolol by more than 75% without 
affecting the alprenolol’s half-life, it did not 
significantly affect the AUC or half-life of the drug 
after its intravenous administration.  
As for Qh, in contrast to the low Eh drugs, the 
pharmacokinetics of high Eh drugs are affected by 
changes in this parameter after both intravenous and 
oral administration. As shown in Table 2, doubling 
Qh hardly affects the Eh value but almost doubles the 
Fh and Clh of the drug. Therefore, the blood 
concentration-time course of the drug after the 
intravenous administration shows a 50% reduction in 
the AUC and half-life (Fig. 4C). The oral profile 
would be affected by changes in both Cl and Fh (Fig. 
4D). After oral dosing, an increase in Cl due to an 
increase in Qh causes a proportional reduction in 
AUC and shortening of half-life. However, an 
increase in Qh also proportionally increases Fh (𝐹௛ ≈
ொ೓
஼௟೔೙೟
) and AUC. Therefore, as demonstrated in Fig. 
4D, the AUC after oral dosing remains the same. 
Please note that the above discussions are based on 
the well-stirred model, which predicts that oral AUC 
is not dependent on Qh for drugs that are eliminated 
by hepatic metabolism: 
 
𝐴𝑈𝐶௉ை =
ி∙஽௢௦௘
஼௟
       (25) 
 
In the above equation, an increase in Qh causes 
proportional increases in both Cl and F, without any 
significant changes in the AUC for a drug with high 
Eh. 
 
Table 2. The pharmacokinetic parameters of a hypothetical druga with high hepatic extraction ratio (Eh) in the absence 
(Control) and presence of changes in the intrinsic capability of the liver to remove the free drug (Cl’int), free drug fraction 
in blood (fub), or hepatic blood flow (Qh) 
Condition Cl’int 
(L/h) 
fub Clint (L/h) Qh 
(L/h) 
Ehb   Fhb   Clhb  
(L/h) 
V 
(L) 
t1/2c 
(h) 
Control 15000 0.1 1500 90 0.943 0.0566 84.9 400 3.26 
 Cl’int x 2 30000 0.1 3000 90 0.971 0.0291 87.4 400 3.17 
 fub x 2 15000 0.2 3000 90 0.971 0.0291 87.4 400 3.17 
 Qh x 2 15000 0.1 1500 180 0.893 0.107 161 400 1.72 
a The hypothetical drug has a Cl’int of 15000 L/h, a fub of 0.1, and a volume of distribution (V) of 400 L under baseline 
conditions, with elimination through the liver only. 
b Eh, Fh, and Clh were estimated from the values of Cl’int, fub, and Qh using Equations 9, 4, and 3, respectively. 
c Half-life (t1/2) is estimated from 𝑡ଵ/ଶ =
଴.଺ଽଷ×௏
஼௟
, where Cl is assumed to be equal to Clh. 
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Figure 4. Effects of a two-fold increase in Clint (fub or Cl’int) (top panels) or Qh (bottom panels) on the blood concentration-
time courses of a hypothetical high Eh drug after intravenous (left) or oral (right) administration of a 400-mg dose of the drug. 
The kinetic parameters are listed in Table 2. 
  
 
An example of the effects of changes in the blood 
flow on the pharmacokinetics in the literature is 
related to the interaction of lidocaine, a high Eh drug, 
with metoprolol and propranolol, which reduce the 
cardiac output and hepatic blood flow (22). 
Lidocaine was administered by a short intravenous 
infusion alone or 1 day after pretreatment with 
metoprolol (50 mg orally every 6 h) or propranolol 
(40 mg orally every 6 h). Metoprolol and propranolol 
reduced the clearance of intravenous lidocaine by 
30% and 50% respectively, presumably due to their 
effects on the hepatic blood flow.  
It should be noted that the changes in the 
clearance, in addition to affecting the half-life of the 
drug, also affects the maximum plasma 
concentration (Cmax) and the time to reach Cmax for 
orally-administered drug.    
 
Oral Clearance and Intrinsic Clearance 
The well-stirred model predicts that the oral 
clearance (Clo or Cl/F) of a drug with hepatic 
elimination alone and no loss in the gastrointestinal 
tract (F = Fh) is in fact equal to its Clint (𝑓௨௕ ∙ 𝐶𝑙௜௡௧ᇱ ), 
therefore, being independent of Qh regardless of 
drug’s Eh: 
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 𝐶𝑙ை =
஽௢௦௘೛೚
஺௎஼೛೚
= ஼௟
ி
= ொ೓×ா೓
ி೓
=
ொ೓×
಴೗೔೙೟
ೂ೓శ಴೗೔೙೟
ೂ೓
ೂ೓శ಴೗೔೙೟
=
𝐶𝑙௜௡௧ = 𝑓௨௕ ∙ 𝐶𝑙௜௡௧ᇱ        (26) 
 
Consequently, it is not surprising that the oral AUC 
is not affected by Qh, as shown in Figs. 3D and 4D 
for the low and high Eh drugs, respectively. Even if 
the Fab and/or Fg values are significantly lower than 
1, Clo is still a function of Clint (and not Qh) as shown 
below: 
 
𝐶𝑙ை =
஽௢௦௘೛೚
஺௎஼೛೚
= ஼௟
ி
= ொ೓×ா೓
ிೌ್×ி೒×ி೓
=
ொ೓×
಴೗೔೙೟
ೂ೓శ಴೗೔೙೟
ிೌ್×ி೒×
ೂ೓
ೂ೓శ಴೗೔೙೟
=
஼௟೔೙೟
ிೌ್×ி೒
       (27) 
 
EXAMPLES OF APPLICATION OF 
CLEARNCE CONCEPTS IN 
INTERPRETATION OF 
PHARMACOKINETIC BEHAVIOR OF 
DRUGS 
 
Estimation of Hepatic Extraction Ratio of Drugs 
from In Vivo Pharmacokinetic Data 
Equation 3 may be rearranged to estimate Eh of a 
drug after its intravenous administration: 
 
𝐸௛ =
஼௟೓
ொ೓
       (28) 
 
After intravenous administration of the drug, the 
systemic Cl is estimated from the blood 
concentration-time data, and an estimate of Clh is 
obtained by either assuming Clh is equal to systemic 
clearance (i.e., for drugs with hepatic elimination 
only) or by subtracting renal Cl from the systemic 
clearance (i.e., for drugs with both renal and hepatic 
elimination), as discussed in detail recently (23). An 
estimate of Eh is then obtained using the calculated 
Clh and an average Qh. The estimates of Eh value can 
then be used to predict the pharmacokinetics and 
blood concentration-time profiles of the drug in the 
presence of changes in the physiologic determinants 
of clearance such as organ blood flow, intrinsic 
clearance, or fub. The assumptions inherent to this 
type of calculation and the ramifications of using 
plasma or serum concentrations, instead of blood 
concentrations, and/or liver plasma flow, instead of 
liver blood flow, were recently discussed in detail 
(23). Briefly, it was shown that if plasma clearance 
and hepatic blood flow are used, the estimated Eh 
would be accurate only if the blood: plasma 
concentration (B:P) ratio of the drug is equal to 1. 
However, the use of the plasma concentrations and 
plasma liver flow will always result in an 
overestimation of the true Eh unless the drug does not 
penetrate the red blood cells (23). 
 
Prediction of Oral Bioavailability from Oral 
Data Only 
In some cases, administration of a drug by 
intravenous method is not feasible or an injectable 
dosage form is not available. Using the clearance 
concepts, and some assumptions, it is possible to 
obtain a rough estimate of the extent of oral 
bioavailability of drugs using oral data only. We 
reported (24) the oral clearance (Clo) of 
tetrabenazine, a drug used for the control of 
movement disorders, in four patients with tardive 
dyskinesia. The Clo values were estimated by 
dividing the oral dose by the AUC. We then used the 
following equation, which is based on Equations 10 
and 26 to estimate Fh in these patients, assuming a 
hepatic blood flow of 1.28 (L/h)/kg and complete 
oral absorption and intestinal availability (i.e., 𝐹 =
𝐹௛): 
 
𝐹 = 𝐹௛ =
ொ೓
ொ೓ା஼௟೔೙೟
= ொ೓
ொ೓ା஼௟೚
       (29) 
 
The estimated F values were 0.05, 0.08, 0.07, 
and 0.02 for patients with Clo values of 431, 252, 299, 
and 1090 (ml/min)/kg, respectively (24). Based on 
these values, we suggested that the oral 
bioavailability (F) of tetrabenazine in humans is very 
low. Indeed, the F value obtained in another study 
(25) after the intravenous and oral administration of 
the drug to humans (0.05) was very close to the 
values obtained from the oral data alone.  
It should be noted that these calculations assume 
elimination by the liver alone (i.e., no renal or 
gastrointestinal clearance). However, a modified 
version of Equation 29 may be provided for drugs 
with both renal and hepatic clearance pathways, as 
shown below: 
 
𝐶𝑙ை =
஼௟
ி
= ஼௟ೝା஼௟೓
ி೓
= ஼௟ೝାொ೓×ா೓
ி೓
=
஼௟ೝାொ೓×(ଵିி೓)
ி೓
= ஼௟ೝାொ೓ିொ೓ி೓
ி೓
       (30) 
 
𝐶𝑙ை × 𝐹௛ = 𝐶𝑙௥ + 𝑄௛ − 𝑄௛𝐹௛       (31) 
 
𝐹௛(𝐶𝑙ை + 𝑄௛) = 𝐶𝑙௥ + 𝑄௛       (32) 
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 𝐹௛ =
஼௟ೝାொ೓
ொ೓ା஼௟೚
       (33) 
 
After determination of Clr and Clo, Equation 33 may 
be used to estimate Fh (or F) for drugs with both 
hepatic and renal elimination. 
 
Differentiation of Gut and Hepatic First-Pass 
Metabolism of Drugs 
An application of clearance concept in the literature 
is for differentiation of first-pass metabolism in the 
gut from that in the liver. After oral administration, 
the oral bioavailability of a drug (F) is a function of 
the fraction of the drug absorbed (Fab), fraction of the 
drug escaping metabolism in the gastrointestinal 
tract (Fg), and fraction of the drug escaping the 
hepatic metabolism or hepatic availability (Fh), as 
demonstrated in Fig. 2 and Equation 24. Once a drug 
is administered by both oral and intravenous routes, 
F may be estimated from the oral and intravenous 
AUC values (correcting for the dose). Additionally, 
the hepatic Eh and Fh may be estimated from the 
intravenous data using Equations 28 and 4, 
respectively, assuming an average Qh of 1500 
mL/min in a 70-kg subject. Consequently, the value 
of 𝐹௔௕ × 𝐹௚  may be estimated from the F and Fh 
values by rearranging Equation 24: 
 
𝐹௔௕ × 𝐹௚ =
ி
ி೓
      (34) 
 
This method allows one to separate the contribution 
of the liver (Fh) from that of the gut (𝐹௔௕ × 𝐹௚) to the 
overall loss of the drug after the oral administration. 
However, in the absence of any additional 
information about the extent of absorption of the 
drug, Fab and Fg cannot be separated from each other.  
An application of this method was demonstrated 
by Hebert et al. (26), who administered a single oral 
(10 mg/kg) or intravenous (3 mg/kg) dose of 
cyclosporine to six healthy subjects and found 
average blood AUC values of 8986 and 10092 
ng.h/mL, respectively. Based on the oral and 
intravenous data, the oral bioavailability (F) of 
cyclosporine in these patients was 0.27: 
 
𝐹 = ஺௎஼ುೀ
஺௎஼೔ೡ
× ஽௢௦௘೔ೡ
஽௢௦௘೛೚
       (35) 
𝐹 =
8986
10092
×
3
10
= 0.27 
 
The systemic clearance of cyclosporine based on the 
intravenous dose of 3 mg/kg and AUCiv of 10092 
was 0.3 L/kg: 
 
𝐶𝑙 =
𝐷𝑜𝑠𝑒௜௩
𝐴𝑈𝐶௜௩
=
3000
10092
= 0.3 L/kg 
 
Assuming the systemic clearance of cyclosporine is 
equal to its hepatic clearance (i.e., gut clearance 
doses not significantly contribute to the systemic 
clearance) and a Qh of 1.286 L/h/kg (90 L/h in a 70-
kg subject), the Eh and Fh values were then 
estimated: 
 
𝐸௛ =
0.3
1.286
= 0.23 
𝐹௛ = 1 − 0.23 = 0.77 
 
Using the predicted Fh and measured F, the 𝐹௔௕ × 𝐹௚ 
value of cyclosporine was then determined: 
 
𝐹௔௕ × 𝐹௚ =
𝐹
𝐹௛
=
0.27
0.77
= 0.35 
 
A comparison of F (0.27), Fh (0.77), and 𝐹௔௕ × 𝐹௚ 
(0.35) values of cyclosporine in these patients, 
clearly suggests that the low oral bioavailability of 
the drug is mostly due to the loss of drug in the 
gastrointestinal tract than its loss during the first-pass 
metabolism in the liver. Later, Galetin et al. (27) used 
this method to estimate the Fg of a number of drugs, 
with an assumption that the absorption of the drugs, 
if experimentally unknown, was complete (Fab = 1).  
 
Differentiation of Incomplete Absorption from 
the First-Pass Metabolism in the Gut and Liver  
Wu et al. (19) proposed a method to determine Fab, 
Fg, and Fh separately, based on the intravenous and 
oral administration of a drug in the absence and 
presence of interacting drugs known to inhibit its 
metabolism. If the interacting and victim drugs are 
administered several hours apart from each other, 
one may assume that the interacting drug would only 
affect the metabolism and not the extent of 
absorption of the victim drug. In that case, the 
following equations may be defined: 
𝐹 = 𝐹௔௕ × 𝐹௚ × 𝐹௛ 
In the Absence of Interaction 
𝐹௜௧௫ = 𝐹௔௕ × 𝐹௚,௜௧௫ × 𝐹௛,௜௧௫ 
In the Presence of Interaction 
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 where the subscript itx indicates the parameter in 
the presence of the interacting drug. The values of 
𝐹௔௕ × 𝐹௚  or 𝐹௔௕ × 𝐹௚,௜௧௫  may be easily estimated 
from F and Fh or Fitx and Fh,itx, respectively, using 
Equation 34. 
In the case of an enzyme inhibitor interaction, 
the value of Fab may be estimated between its two 
minimum and maximum boundaries. The maximum 
boundary of Fab is 1. The minimum boundary of Fab 
is assuming Fg,itx is equal to 1 (i.e., complete 
inhibition of gut metabolism). Setting Fab to its 
maximum (i.e., 1) or minimum (calculated from the 
enzyme inhibition data) boundaries, the values of Fg 
in control subjects (i.e., the absence of drug 
interaction) may be estimated between a minimum 
and a maximum.  
The method was used to determine the 
contribution of hepatic and gastrointestinal first-pass 
metabolism to the overall F of cyclosporine in the 
presence and absence of two enzyme inhibitors 
(erythromycin and ketoconazole) and an enzyme 
inducer (rifampin) (19). Here, we present the data 
(28) and calculations (19) for the ketoconazole 
inhibition study, which was conducted in five 
healthy subjects. The doses and average blood AUC 
values after the oral and intravenous administration 
of cyclosporine in the absence (Control) and 
presence of ketoconazole are listed in Table 3 (28). 
Using the average values presented in Table 3, 
The F, Fh, and 𝐹௔௕ × 𝐹௚ values in Control subjects 
may be estimated as shown below: 
 
𝐹 =
𝐴𝑈𝐶௉ை
𝐴𝑈𝐶௜௩
×
𝐷𝑜𝑠𝑒௜௩
𝐷𝑜𝑠𝑒௣௢
=
5938
6683
×
0.5
2
= 0.222 
 
𝐶𝑙 =
𝐷𝑜𝑠𝑒௜௩
𝐴𝑈𝐶௜௩
=
2000
6683
= 0.299 𝐿/ℎ/𝑘𝑔 
 
𝐹௛ = 1 − 𝐸௛ = 1 −
𝐶𝑙௛
𝑄௛
= 1 −
0.299
1.28
= 1 − 0.234
= 0.766 
 
𝐹௔௕ × 𝐹௚ =
𝐹
𝐹௛
=
0.222
0.766
= 0.290 
 
Similarly, Fitx, Fh,itx, and 𝐹௔௕ × 𝐹௚,௜௧௫ in the presence 
of ketoconazole may be calculated using the 
respective data in Table 3. The summary of the above 
calculations, based on the average AUC value 
reported before (28), are presented in Table 4. 
The data in the presence of ketoconazole, 
presented in Table 4, suggest that two boundaries of 
Fab are 1 and 0.722. Consequently, Fg may be 
estimated at these two boundaries: 
 
𝐹௔௕ × 𝐹௚ = 0.290 
 
𝐹௚ =
0.290
𝐹௔௕
 
 
𝐹௚ି௟௢௪ =
0.290
1
= 0.290 
 
𝐹௚ି௨௣௣ =
0.290
0.722
= 0.402 
 
Therefore, the lower ( 𝐹௚ି௟௢௪ ) and upper 
(𝐹௚ି௨௣௣ ) limits of Fg for cyclosporine in healthy 
volunteers are 0.290 and 0.402, whereas the lower 
and upper limits of Fab are 0.722 and 1, respectively. 
Considering an Fh of 0.766 (Table 4), the data 
suggest that the low oral bioavailability of 
cyclosporine in Control subjects (0.222) is indeed 
mostly due to its first-pass metabolism in the gut (Fg 
of 0.290-0.402), whereas the oral absorption of the 
formulation is relatively high (Fab of 0.722-1.0). 
Again, these calculations assume that gut clearance, 
although reducing the presystemic availability of the 
drug, does not significantly contribute to the 
systemic clearance of the drug, meaning that Cl is 
equal to Clh.  
More recently, Hisaka et al. (29) developed a 
new method based on the concept of drug-drug 
interactions to estimate Fg values from the changes 
in the AUC and half-life values of the victim drug in 
the presence of the perpetrating drug. The method is 
based on the idea that the inhibition of intestinal 
metabolism causes a change in the AUC without any 
changes in the plasma half-life. However, inhibition 
of hepatic metabolism results in changes in both half-
life and AUC, unless the clearance of the drug is 
flow-limited (i.e., drugs with high extraction ratio). 
Nevertheless, the method still requires an 
approximation of Fab value. Using this method, the 
authors estimated Fg values of 0.56 ± 0.29 (mean ± 
SD) for 20 drugs that were CYP3A substrates and 
0.86 ± 0.11 for 8 drugs that were not CYP3A 
substrates. The interested readers are referred to the 
original article (29) for details about the method and 
derivation of equations.   
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Estimation of Gastrointestinal Availability from 
Grapefruit Juice-Drug Interaction Studies 
Grapefruit juice (GFJ) components are believed to 
irreversibly inhibit intestinal CYP3A4, without any 
major effect on the liver CYP3A4 (30). Therefore, 
co-administration of grapefruit juice with an orally-
administered drug that is subject to intestinal 
CYP3A4 metabolism inhibits the drug’s CYP3A4-
mediated, presystemic intestinal metabolism. Gertz 
et al. (31) used available data in the literature related 
to the interaction of drugs with grapefruit juice to 
estimate their Fg, using the following equation: 
 
𝐹௚ =
஺௎஼಴೚೙೟ೝ೚೗
஺௎஼ಸಷ಻
       (36) 
 
where AUCControl and AUCGFJ are the AUC of the 
drug in the absence and presence of GFJ 
administration, respectively. This method assumes 
complete intestinal metabolism of the drug through 
CYP3A4, complete inhibition of intestinal 
metabolism with GFJ, and no effect of GFJ on the 
systemic (liver) metabolism or clearance or the 
extent of absorption (Fab) of the drug. Additionally, 
the authors (31) suggested that the method’s 
applicability to drugs that are subject to transport or 
efflux in the gastrointestinal tract is limited. 
 
LIMITATIONS 
It should be noted that while clearance concepts are 
very useful in predicting the pharmacokinetic 
behavior of drugs, their applications to estimation of 
F and its components (Fab, Fg, and Fh) in different 
situations presented here are associated with a 
number of assumptions, hence subject to some 
degree of error. First, the AUC and clearance terms 
in the above equations are based on the blood 
concentrations of the drug. Therefore, the use of 
plasma values, which are commonly measured, may 
introduce substantial errors in the estimation of the 
kinetic parameters (23). Second, a number of 
calculations listed above use an average liver blood 
flow (e.g., 1500 mL/min), which might be different 
than the actual Qh in the studied subjects. This is 
because although intra-  and inter-individual 
variabilities in the hepatic blood flow in healthy 
subjects under controlled conditions appears to be 
relatively low (32-34), physiological factors (e.g., 
posture and exercise), pharmacological interventions 
(e.g., beta-blockers), disease states (e.g., heart 
failure), or food ingestion may significantly affect 
hepatic blood flow (35, 36). Other assumptions 
include linear pharmacokinetics and a constant 
systemic clearance after different routes of 
administration. With specific reference to methods 
estimating Fg, additional assumptions are that the 
intestinal clearance, although reducing the 
presystemic availability of the drug, does not 
significantly contribute to the systemic clearance of 
the drug. Lastly, estimation of Fg is also based on the 
assumption that the drug is not subject to influx or 
efflux transporters. Nevertheless, despite these 
assumptions and/or limitations, application of 
clearance concepts has resulted in substantial 
improvement in our understanding of the 
pharmacokinetics of many drugs.      
 
 
Table 3. The dose and average AUC values of cyclosporine after intravenous and oral administration of the drug to healthy 
subjects in the absence (Control) and presence of ketoconazolea 
 Dose, mg/kg  AUC, ng.h/mL 
 Intravenous Oral  Intravenous Oral 
Control 2 8  6683 5938 
Plus Ketoconazole 0.5 2  3120 7883 
a Data from reference (28). 
Table 4. The calculated oral bioavailability (F) and estimated hepatic availability (Fh) and products of fraction absorbed 
(Fab) and gut availability (Fg) of cyclosporine in the absence (Control) and presence of ketoconazolea 
 F Fh  Fab . Fg 
Control 0.222 0.766 0.290 
Plus Ketoconazole 0.632 0.875 0.722 
a Calculations are based on the average AUC values and doses presented in Table 3.  
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 CONCLUSIONS 
 
In conclusion, development of clearance concepts 
has significantly moved the discipline of 
pharmacokinetics forward. Although clearance 
concepts are more discussed in terms of hepatic 
clearance, they are equally applicable to clearance by 
other eliminating organs, such as the kidneys. The 
concepts allow definition of organ and total 
clearance values in terms of physiologic parameters 
such as organ blood flow and intrinsic capability of 
the eliminating organ to remove the drug from the 
body. Furthermore, the clearance concepts allow 
prediction of the pharmacokinetics of drugs after 
intra- and extravascular routes in the presence of 
disease states, drug interactions, or as a result of 
patients’ age. Researchers have applied these 
concepts to predict the oral bioavailability of drugs 
in the absence of otherwise needed intravenous data, 
to distinguish between the role of liver and gut in the 
first pass metabolism of drugs, and to differentiate 
between the incomplete oral absorption and 
metabolism in the gut after oral administration of 
drugs. More than 45 years after their introduction, 
clearance concepts remain a powerful tool in 
explaining the pharmacokinetics of drugs and 
predicting the changes in the blood concentration-
time course of drugs when the underlying 
physiologic parameters are altered.   
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